The results further showed that the OS, event-free survival (EFS) and progression-free survival (PFS) of MM patients with higher levels of YTHDF2 expression was shorter than that of patients with low YTHDF2 expression (Fig. 1F, Supplementary Fig. 1F–J). This evidence concerns the gene YTHDF2 and Miyoshi myopathy.